BioCentury
ARTICLE | Financial News

Ziopharm planning $50 million follow-on

October 23, 2013 12:48 AM UTC

Ziopharm Oncology Inc. (NASDAQ:ZIOP) late Tuesday proposed to raise $50 million in a follow-on underwritten by JPMorgan. Ziopharm said partner Intrexon Corp. (NYSE:XON) may purchase up to $10 million of shares in the offering. Ziopharm's Ad-RTS-IL-12 is in Phase II testing to treat metastatic melanoma and non-resectable recurrent or metastatic breast cancer, with preliminary data from both trials expected this quarter. The product is a DNA vector that contains an inducible promoter to control expression of the IL-12 gene. Ziopharm has exclusive, worldwide rights to Intrexon's synthetic biology technology to develop and commercialize DNA-based therapeutics for cancer indications. ...